Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer
Figure 3
RASSF1A and RASSF2A methylation profiles of different histology. RASSF1A was methylated in 68% (28/41) of transitional cell carcinoma samples, in 100% (4/4) of small cell carcinoma and in 67% (2/3) of squamous cell carcinoma. RASSF2A was methylated in 7% (3/41) of transitional cell carcinoma samples, in 0% (0/4) of small cell carcinoma, and in 33% (1/3) of squamous cell carcinoma.
